Alzheimer's Disease - Pipeline Review, H1 2014, New Report Launched

Alzheimer's Disease - Pipeline Review, H1 2014 report provides an overview of the Alzheimer's Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

• The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Alzheimer's Disease and enlists all their major and minor projects
• A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• Coverage of the Alzheimer's Disease pipeline on the basis of target, MoA, route of administration and molecule type.

Spanning over 1242 pages, “Alzheimer's Disease - Pipeline Review, H1 2014” report covering the Introduction, Alzheimer's Disease Overview, Therapeutics Development, Drug Profiles, Appendix. The report covered few companies are - Bristol-Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Biogen Idec Inc., OXIS International, Inc., Shionogi & Co., Ltd., NsGene A/S, Amgen Inc., Sanofi

Know more about this report at – http://mrr.cm/ZVd